Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden. Issue 6 (June 2022)

• Record Type: Journal Article
• Authors: Gonçalves, Bronner P; Procter, Simon R; Paul, Proma; Chandna, Jaya; Lewin, Alexandra; Seedat, Farah; Koukounari, Artemis; Dangor, Ziyaad; Leahy, Shannon; Santhanam, Sridhar; John, Hima B; Bramugy, Justina; Bardají, Azucena; Abubakar, Amina; Nasambu, Carophine; Libster, Romina; Sánchez Yanotti, Clara; Horváth-Puhó, Erzsébet; Sørensen, Henrik T; van de Beek, Diederik; Bijlsma, Merijn W; Gardner, William M; Kassebaum, Nicholas; Trotter, Caroline; Bassat, Quique; Madhi, Shabir A; Lambach, Philipp; Jit, Mark; Lawn, Joy E
• Is Part Of: Lancet. Volume 10:Issue 6(2022)
• Page Start: e807
• Page End: e819
• Publication Date: 2022-06
• Subjects: World health -- Periodicals; 362.105
• DOI: 10.1016/S2214-109X(22)00093-6
• Languages: English
• ISSNs: 2214-109X

Abstract

Summary: Background: Group B streptococcus (GBS) colonisation during pregnancy can lead to invasive GBS disease (iGBS) in infants, including meningitis or sepsis, with a high mortality risk. Other outcomes include stillbirths, maternal infections, and prematurity. There are data gaps, notably regarding neurodevelopmental impairment (NDI), especially after iGBS sepsis, which have limited previous global estimates. In this study, we aimed to address this gap using newly available multicountry datasets. Methods: We collated and meta-analysed summary data, primarily identified in a series of systematic reviews published in 2017 but also from recent studies on NDI and stillbirths, using Bayesian hierarchical models, and estimated the burden for 183 countries in 2020 regarding: maternal GBS colonisation, iGBS cases and deaths in infants younger than 3 months, children surviving iGBS affected by NDI, and maternal iGBS cases. We analysed the proportion of stillbirths with GBS and applied this to the UN-estimated stillbirth risk per country. Excess preterm births associated with maternal GBS colonisation were calculated using meta-analysis and national preterm birth rates. Findings: Data from the seven systematic reviews, published in 2017, that informed the previous burden estimation (a total of 515 data points) were combined with new data (17 data points) from large multicountry studies on neurodevelopmental impairment (two studies) and stillbirths (one study). A posterior median of 19·7 million (95% posterior interval 17·9–21·9) pregnant women were estimated to have rectovaginal colonisation with GBS in 2020. 231 800 (114 100–455 000) early-onset and 162 200 (70 200–394 400) late-onset infant iGBS cases were estimated to have occurred. In an analysis assuming a higher case fatality rate in the absence of a skilled birth attendant, 91 900 (44 800–187 800) iGBS infant deaths were estimated; in an analysis without this assumption, 58 300 (26 500–125 800) infant deaths from iGBS were estimated. 37 100 children who recovered from iGBS (14 600–96 200) were predicted to develop moderate or severe NDI. 40 500 (21 500–66 200) maternal iGBS cases and 46 200 (20 300–111 300) GBS stillbirths were predicted in 2020. GBS colonisation was also estimated to be potentially associated with considerable numbers of preterm births. Interpretation: Our analysis provides a comprehensive assessment of the pregnancy-related GBS burden. The Bayesian approach enabled coherent propagation of uncertainty, which is considerable, notably regarding GBS-associated preterm births. Our findings on both the acute and long-term consequences of iGBS have public health implications for understanding the value of investment in maternal GBS immunisation and other preventive strategies. Funding: Bill & Melinda Gates Foundation.